What is Bliss GVS Pharma Ltd (BLISSGVS) share price return in the past 10 years?

Bliss GVS Pharma Ltd share price has appreciated 18.9% annually (CAGR) over the past ten years.

What is the share price of Bliss GVS Pharma Ltd (BLISSGVS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Bliss GVS Pharma Ltd (BLISSGVS) on 02-Jul-2026 16:59:59 at 16:59 is 526.50.

What is the P/E ratio of Bliss GVS Pharma?

The latest standalone P/E ratio of Bliss GVS Pharma as of 02-Jul-2026 is 57.64.

What is the P/B ratio of Bliss GVS Pharma Ltd (BLISSGVS)?

The latest standalone P/B ratio of Bliss GVS Pharma Ltd (BLISSGVS) as of 02-Jul-2026 is 4.88.

What is the 52-week high and low of Bliss GVS Pharma Ltd (BLISSGVS)?

The 52-week high of Bliss GVS Pharma Ltd (BLISSGVS) is Rs. 552.90 and the 52-week low is Rs. 118.35.

Bliss GVS Pharma Ltd (BLISSGVS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Bliss GVS Pharma Ltd (BLISSGVS)
Brand: Bliss GVS Pharma

Bliss GVS Pharma Ltd (BLISSGVS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506197 NSE: BLISSGVS Pharmaceuticals & Drugs | Small Cap | Bliss GVS Pharma Share Price

Bliss GVS Pharma Ltd (BLISSGVS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506197 NSE: BLISSGVS Pharmaceuticals & Drugs | Small Cap | Bliss GVS Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹5,584 Cr.

Current Price

₹526.5

52-Week Low / High

₹118 / 553

TTM EPS

₹9.1

TTM Sales

₹730 Cr.

Book Value per Share

₹107.8

P/E Ratio

57.64

Higher than its 5-year historical median

Industry PE

49.2

Price to Book (P/B)

4.88

Higher than its 5-year historical median

Price to Sales (P/S)

7.65

Higher than its 5-year historical median

EV/EBITDA

30.79

Higher than its 5-year historical median

Dividend Yield

0.28%

Profitability Efficiency

Return on Equity (ROE)

8.82%

In line with industry median

Return on Capital Employed (ROCE)

12.77%

Outperforms industry median

Return on Assets (ROA)

7.63%

Operating Profit Margin

16.4%

Net Profit Margin

13.27%

Gross Profit Margin

21.6%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

9.38%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

30.18%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

40.45%

Asset Quality

Promoter Holding

35.36%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹1,133 Cr.

Equity

₹10.6 Cr.

Face Value

₹1

All Time Low / High

₹0.04 / 552.90

Bliss GVS Pharma stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Bliss GVS Pharma Ltd a good quality company?

Bliss GVS Pharma Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Bliss GVS Pharma Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Bliss GVS Pharma Ltd vs industry peers?

Bliss GVS Pharma Ltd revenue CAGR is 8.59%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Bliss GVS Pharma Ltd?

Promoters hold 35.36% of the Bliss GVS Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Bliss GVS Pharma Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 10.9% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	19.3%	15.6%	18.8%	17.8%	12%	14.7%	12.9%	7.4%	9.3%	12.8%	-
Value Creation Index ⓘ	0.4	0.1	0.3	0.3	-0.1	0.1	-0.1	-0.5	-0.3	-0.1	-
Growth Parameters ⓘ
Sales ⓘ	348	298	427	442	466	636	598	605	667	730	730
Sales YoY Gr.	-	-14.4%	43.2%	3.6%	5.3%	36.7%	-6%	1.2%	10.2%	9.4%	-
Adj EPS ⓘ	5.8	5.2	5.4	7	6	7.5	5.6	6.6	5.2	7.6	9.1
YoY Gr.	-	-10.8%	4.3%	29.6%	-13.2%	23.3%	-24.7%	16.8%	-20%	44.9%	-
BVPS (₹) ⓘ	47.7	52.5	58.5	66.2	72.3	81.2	89.1	93.7	99.9	108.1	107.8
Adj Net Profit ⓘ	59.5	53.2	55.3	71.8	62.3	77.3	58.4	68.6	55.2	80.3	97
Cash Flow from Ops. ⓘ	38.5	22.7	48.3	63.2	67	114	43.8	82.2	97.2	123	-
Debt/CF from Ops. ⓘ	2	4.1	1.5	1.4	1.3	0.8	1.8	0.8	0.5	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.6%	9.4%	6.8%	9.4%
Adj EPS ⓘ	3.1%	4.7%	10.6%	44.9%
BVPSⓘ	9.5%	8.4%	6.7%	8.2%
Share Price	18.9%	37.2%	87.3%	236.4%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	12.9	10.3	9.7	11.2	8.7	9.6	6.5	7.1	5.4	7.3	8.5
Op. Profit Mgn % ⓘ	29	29.7	22.4	22.7	19.7	17.2	15.1	17.7	13.8	16.4	16.7
Net Profit Mgn % ⓘ	17.1	17.9	13	16.2	13.4	12.1	9.8	11.3	8.3	11	13.3
Debt to Equity ⓘ	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0
Working Cap Days ⓘ	533	621	442	443	471	372	419	400	326	332	184
Cash Conv. Cycle ⓘ	206	270	269	307	293	212	233	242	223	208	146

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	348	298	427	442	466	636	598	605	667	730
Operating Expenses ⓘ +	247	209	333	342	374	527	508	498	576	611
Manufacturing Costs	6	6	8	11	14	18	17	26	25	33
Material Costs	167	146	225	237	253	344	315	299	346	343
Employee Cost	25	26	34	44	59	65	73	83	99	121
Other Costs ⓘ	49	31	67	50	48	100	104	90	105	113
Operating Profit ⓘ	101	88	93	100	91	109	90	107	92	119
Operating Profit Margin (%)	28.9%	29.7%	21.8%	22.7%	19.6%	17.2%	15.1%	17.7%	13.7%	16.3%
Other Income ⓘ +	9	11	36	37	19	33	51	34	36	59
Exceptional Items ⓘ	0	0	0	0	0	3	0	-41	0	-2
Interest ⓘ	9	7	3	7	6	4	10	6	7	11
Depreciation ⓘ	6	6	6	9	14	14	15	24	27	31
Profit Before Tax ⓘ	95	87	120	122	91	126	116	70	94	133
Tax ⓘ	36	30	46	29	24	34	30	20	25	37
Profit After Tax	59	57	74	92	68	93	85	51	69	97
PAT Margin (%)	17.0%	19.1%	17.5%	20.9%	14.5%	14.6%	14.3%	8.4%	10.3%	13.3%
Adjusted EPS (₹)	5.7	5.5	7.2	9.0	6.5	8.9	8.2	4.8	6.6	9.2
Dividend Payout Ratio (%)	10.50%	18.10%	13.90%	5.60%	7.60%	5.60%	6.10%	10.30%	7.60%	16.40%

Valuation of Bliss GVS Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	492	541	603	683	746	841	928	981	1,052	1,144
Share Capital ⓘ	10	10	10	10	10	10	10	10	11	11
Reserves ⓘ	481	531	593	673	735	831	918	970	1,042	1,133
Debt +	74	88	67	71	68	65	66	46	23	0
Long Term Debt	12	6	31	36	32	23	41	35	20	0
Short Term Debt	61	83	37	36	35	41	25	11	3	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	64	35	31	56	67	84	76	54	60	96
Others Liabilities ⓘ	37	29	35	45	65	90	70	65	75	89
Total Liabilities ⓘ	666	694	736	855	946	1,080	1,140	1,146	1,211	1,329
Fixed Assets
Net Fixed Assets ⓘ +	75	72	78	179	174	224	325	330	368	420
Gross Block	81	83	93	202	211	270	385	413	478	555
Accumulated Depreciation	6	11	15	23	37	45	60	84	110	135
CWIP ⓘ	2	0	43	0	2	22	3	8	21	4
Investments ⓘ	22	19	19	19	18	18	18	19	19	19
Inventories	28	40	55	61	84	90	74	89	82	111
Trade Receivables	239	283	342	405	349	409	399	400	429	457
Cash Equivalents	84	70	93	87	120	149	85	169	171	111
Others Assets ⓘ	216	209	105	105	199	167	236	131	122	208
Total Assets ⓘ	666	694	736	855	946	1,080	1,140	1,146	1,211	1,329

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	38	23	48	63	67	114	44	82	97	123
PBT ⓘ	95	87	120	122	91	124	116	111	94	133
Adjustment ⓘ	28	1	3	3	41	35	41	44	56	70
Changes in Working Capital ⓘ	-47	-29	-26	-30	-43	-14	-76	-44	-23	-42
Tax Paid ⓘ	-37	-36	-50	-32	-23	-30	-38	-29	-30	-38
Cash Flow From Investing Activity ⓘ +	-29	16	-68	-60	-62	-92	-13	-66	-78	-51
Capex	-3	-1	-59	-67	-8	-73	-94	-38	-67	-59
Net Investments	-32	3	0	0	0	3	0	44	-16	-60
Others ⓘ	5	14	-9	7	-54	-22	81	-71	5	67
Cash Flow From Financing Activity ⓘ +	-15	-22	9	-6	-12	-13	-26	-21	-27	-75
Net Proceeds from Shares ⓘ	0	0	0	0	0	2	2	2	3	2
Net Proceeds from Borrowing ⓘ	0	0	24	13	2	-5	-16	-10	-15	-48
Interest Paid ⓘ	-9	-8	-3	-4	-6	-2	-6	-5	-5	-14
Dividend Paid ⓘ	-5	-6	-12	-12	-6	-5	-5	-5	-5	-11
Others ⓘ	-0	-8	0	-2	-2	-2	-1	-3	-4	-5
Net Cash Flow ⓘ	-6	17	-11	-3	-6	9	5	-4	-7	-4

Financial Ratio

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	12.8	11.04	13	14.36	9.45	11.68	9.66	5.31	6.78	8.82
ROCE (%)	19.25	15.6	18.8	17.75	12.02	14.68	12.89	7.36	9.31	12.77
Asset Turnover Ratio	0.51	0.44	0.6	0.56	0.52	0.63	0.54	0.53	0.59	0.61
PAT to CFO Conversion(x)	0.64	0.4	0.65	0.68	0.99	1.23	0.52	1.61	1.41	1.27
Working Capital Days
Receivable Days	255.30	319.30	267.20	308.50	295.40	217.20	246.40	240.70	215.90	209.20
Inventory Days	26.10	41.50	40.50	47.70	56.60	49.80	50.10	49.30	44.70	45.60
Payable Days	107.90	124.10	53.70	66.90	88.40	80.10	92.80	79.40	60.50	83.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bliss GVS Pharma Ltd FAQs

The current trading price of Bliss GVS Pharma on 02-Jul-2026 16:59 is ₹526.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Bliss GVS Pharma stood at ₹5,583.9 Cr

The latest P/E ratio of Bliss GVS Pharma as of 01-Jul-2026 is 57.64.

The latest P/B ratio of Bliss GVS Pharma as of 01-Jul-2026 is 4.88.

The 52-week high of Bliss GVS Pharma is ₹552.9 and the 52-week low is ₹118.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bliss GVS Pharma is ₹730 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a average quality company.

The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Bliss GVS Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Bliss GVS Pharma Ltd

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
2011: EU-GMP approval to the manufacturing facility for suppository facility.
2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
2017: Setting up offices in South East Asian countries.
2018: Divestment from Bliss GVS Healthcare.
2019: Setting up of multi-dosage facility (Vevoor Plant).

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Bliss GVS Pharma Ltd (BLISSGVS)

Bliss GVS Pharma Ltd (BLISSGVS)

Bliss GVS Pharma stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Bliss GVS Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bliss GVS Pharma Ltd FAQs

What is the share price of Bliss GVS Pharma?

What is the market cap of Bliss GVS Pharma?

What is the P/E ratio of Bliss GVS Pharma?

What is the P/B ratio of Bliss GVS Pharma?

What is the 52-week high and low of Bliss GVS Pharma?

What is the TTM revenue of Bliss GVS Pharma?

Is Bliss GVS Pharma Ltd a good quality company?

Is Bliss GVS Pharma Ltd undervalued or overvalued?

Is Bliss GVS Pharma Ltd a good buy now?

About Bliss GVS Pharma Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.